University Institute of Pharmaceutical Sciences, UGC-Centre of Advanced Study Panjab University, Chandigarh 160014, India.
University Institute of Pharmaceutical Sciences, UGC-Centre of Advanced Study Panjab University, Chandigarh 160014, India.
J Control Release. 2014 Nov 10;193:100-12. doi: 10.1016/j.jconrel.2014.05.031. Epub 2014 May 24.
It is assumed that more than 50% of the most enfeebling ocular diseases have their origin in the posterior segment. Furthermore, most of these diseases lead to partial or complete blindness, if left untreated. After cancer, blindness is the second most dreaded disease world over. However, treatment of posterior eye diseases is more challenging than the anterior segment ailments due to a series of anatomical barriers and physiological constraints confronted for delivery to this segment. In this regard, nanostructured drug delivery systems are proposed to defy ocular barriers, target retina, and act as permeation enhancers in addition to providing a controlled release. Since an important step towards developing effective treatment strategies is to understand the course or a route a drug molecule needs to follow to reach the target site, the first part of the present review discusses various pathways available for effective delivery to and clearance from the posterior eye. Promise held by nanocarrier systems, viz. liposomes, nanoparticles, and nanoemulsion, for effective delivery and selective targeting is also discussed with illustrative examples, tables, and flowcharts. However, the applicability of these nanocarrier systems as self-administration ocular drops is still an unrealized dream which is in itself a huge technological challenge.
据推测,超过 50%的最使人虚弱的眼部疾病都起源于后段。此外,如果不治疗,这些疾病中的大多数会导致部分或完全失明。仅次于癌症,失明是全世界第二大致人畏惧的疾病。然而,由于一系列的解剖学障碍和生理限制,使得向该部位输送药物变得极具挑战性,后眼部疾病的治疗比前段疾病更具挑战性。在这方面,纳米结构药物传递系统被提议用于克服眼部屏障、靶向视网膜,并充当渗透增强剂,此外还提供了控制释放。由于朝着开发有效治疗策略迈出的重要一步是了解药物分子需要遵循的途径或路线,以到达靶位,因此本综述的第一部分讨论了有效递送至后眼部和从后眼部清除的各种途径。还讨论了纳米载体系统(例如脂质体、纳米颗粒和纳米乳剂)在有效递送和选择性靶向方面的潜力,并提供了说明性示例、表格和流程图。然而,这些纳米载体系统作为自我管理的眼部滴剂的适用性仍然是一个尚未实现的梦想,这本身就是一个巨大的技术挑战。